CA2859930A1 - A cannabis topical from heat treated cocount oil - Google Patents
A cannabis topical from heat treated cocount oil Download PDFInfo
- Publication number
- CA2859930A1 CA2859930A1 CA2859930A CA2859930A CA2859930A1 CA 2859930 A1 CA2859930 A1 CA 2859930A1 CA 2859930 A CA2859930 A CA 2859930A CA 2859930 A CA2859930 A CA 2859930A CA 2859930 A1 CA2859930 A1 CA 2859930A1
- Authority
- CA
- Canada
- Prior art keywords
- cannabis
- mixture
- topical
- topical composition
- composition prepared
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
- A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
- A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dermatology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Neurology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
A method is disclosed whereby by two subspecies of cannabis (Indica and Sativa) are mixed in equal weight portions, followed by repeated heating and congealing of the mixture in Virgin Coconut Oil to yield a topical lotion for use in the treatment of arthritic muscle and joint pain. Concentrations of the major cannabinoid actives in the lotion are determined using laboratory analysis by High Pressure Liquid Chromatography (HPLC).
Description
, r A Cannabis Topical from Heat Treated Coconut Oil Inventors:
1. Erik William Mikkelsaar 987 Balfour Street Fenwick, Ontario Industry I ndustn e Y/N liD
LOS 1C0 Canada Canada
1. Erik William Mikkelsaar 987 Balfour Street Fenwick, Ontario Industry I ndustn e Y/N liD
LOS 1C0 Canada Canada
2. Antony Paul Hornby, Ph.D.
P.O. Box 22008 SIAM I PI a Richmond, B.C. CIPO OPIC
Abstract [0001] A method is disclosed whereby by two subspecies of cannabis (Indica and Sativa) are mixed in equal weight portions, followed by repeated heating and congealing of the mixture in Virgin Coconut Oil to yield a topical lotion for use in the treatment of arthritic muscle and joint pain. Concentrations of the major cannabinoid actives in the lotion are determined using laboratory analysis by High Pressure Liquid Chromatography (HPLC).
Background to the Invention [0002] Patent No. W02004016277 teaches an extraction method using super critical fluid extraction of cannabinoids from plant material the method described here uses no fluid extraction procedure and does not substitute with synthetic analogues if extracted material is not available.
P.O. Box 22008 SIAM I PI a Richmond, B.C. CIPO OPIC
Abstract [0001] A method is disclosed whereby by two subspecies of cannabis (Indica and Sativa) are mixed in equal weight portions, followed by repeated heating and congealing of the mixture in Virgin Coconut Oil to yield a topical lotion for use in the treatment of arthritic muscle and joint pain. Concentrations of the major cannabinoid actives in the lotion are determined using laboratory analysis by High Pressure Liquid Chromatography (HPLC).
Background to the Invention [0002] Patent No. W02004016277 teaches an extraction method using super critical fluid extraction of cannabinoids from plant material the method described here uses no fluid extraction procedure and does not substitute with synthetic analogues if extracted material is not available.
[0003] Patent No. US2003191180 speaks to organic solvent extraction of cannabinoids from plant material plus the use of the invention of synthetic analogues.
The patent described here references only natural product material and coconut oil for extraction.
The patent described here references only natural product material and coconut oil for extraction.
[0004] Patent No. W003063847 teaches anti-nausea formulation based on solvent extraction of THC-A. In the patent described here no extraction precedes activation of THC-A to THC.
[0005] Patent No. US2002086438 again teaches an organic solvent extraction of cannabinoids to be used in medicinal formulations plus a chelation step for ^-as a concentration enhancer. This patent describes the use of virgin coconut oil as the extraction solvent.
[0006] Patent No. US20120264818 Al speaks to an aprotic solvent (methyl sulfoxide) for extraction of cannabinoids. This patent uses a heat processed, virgin coconut oil.
[0007] The efficacy of cannabis medicine has been known for many years across a broad range of ailments from addiction withdrawal to tremor. In addition, many thousands of years use with no evidence of fatal overdose lends great credence to its safety. However, as the result of roughly 100 years of prohibition in most of the western world its utilization as a medicine has yet to be realized.
[0008] Since the discovery of the receptor for ^9-tetrahydrocannabinol (THC.
cannabis' principle active) in the early 1990's, there's been an enormous resurgence in medical cannabis research, once again pointing the way to its efficacy and safety.
The former parameter, efficacy has problems in terms of the traditional means of administration (smoking) and oral dosing in that accurate dosing is not possible with unstandardized preparations and overdose (although not fatal, can be frightening) will occur.
cannabis' principle active) in the early 1990's, there's been an enormous resurgence in medical cannabis research, once again pointing the way to its efficacy and safety.
The former parameter, efficacy has problems in terms of the traditional means of administration (smoking) and oral dosing in that accurate dosing is not possible with unstandardized preparations and overdose (although not fatal, can be frightening) will occur.
[0009] Topical applications as a result of relatively slow uptake through the epidermis as a rule do not cause overdose and can be considered safer for this reason.
Topical administration is often advantageous for arthritic pain, since application can be made directly to the painful sight (hands, back, joints).
Topical administration is often advantageous for arthritic pain, since application can be made directly to the painful sight (hands, back, joints).
[0010] Cannabinoids are highly fat-soluble compounds and therefore readily dissolve in non-polar, hydrocarbon-like environments such as oils. Coconut oil contains an unusually high percentage of saturated fat (making it unsuitable for human oral consumption) and is therefore slow to oxidize and turn rancid. The virgin coconut oil also contains a relatively high content of medium chain triglycerides, plus lauric acid.
It is the unusual fat profile of coconut oil that elicits the unique heating and congealing properties of the oil, making it useful as an extracting solvent, plus penetrator.
It is the unusual fat profile of coconut oil that elicits the unique heating and congealing properties of the oil, making it useful as an extracting solvent, plus penetrator.
[0011] Repeated heating (130-150 C) and cooling of the oil greatly enhances the penetrating and delivery action, whereby viscosity. free fatty acid changes and oxidation lend to the desired preparation over a repeated heating and cooling cycle.
[0012] Addition of a 50:50 (by weight Indica ssp./Sativa ssp.) of the dried, ground, leaves and flowers of the cannabis plant (at approximately 5g cannabis raw material per 30 ml oil) to the mix, prior to heating is added to a slow cooker (Rival Crock Pot, model 3355, rated at 250 watts. 120 volts 50-60 cycle, CSA approved) and the temperature raised to between 146-149 C (295-300 F) for 5-7 hours, with occasional mixing.
[0013] The heat is then turned off and the mixture allowed to cool to the point of congealing (at roughly 23 C), often taking overnight. This cycle is repeated 5 times.
[0014] The heat-treated coconut oil containing the extracted cannabinoids is then strained through a 220-mesh extractor bag, into a suitably sized glass collection vessel and allowed to congeal. A sample of the finished product is taken for HPLC
testing.
[00151 Determining the cannabinoid concentration of the finished product is essential knowledge of dosage and effect. This was done by measuring (by HPLC) the total decarboxy lated ^9-THC, plus the same for cannabidiol (CBD) and cannabinol (CBN).
also known is the amount of Cannabichromene (CBC) and Cannabigerol (CBG), present per milliliter of lotion.
[0016] Infusions such as those described [0011-0015] will provide concentrations of activated THC a 10mg/m1 or greater, depending on starting raw material.
Claims:
[0017] 1. A topical composition is disclosed whereby a 50:50 mixture of cannabis Indica and Sativa are extracted through coconut oil that has been heated (146-149 C) and cooled to congealing (28 C). The infusion is then, re-heated, filtered and tested for active THC concentration by HPLC.
[0018] 2. A topical composition prepared by the process of claim 1, whereby the mixture of cannabis is negated for Indica only.
[0019] 3. A topical composition prepared by the process of claim 1, whereby the mixture of cannabis is negated for Sativa only.
[0020] 4. A topical composition prepared by the process of claim 1, whereby the mixture of cannabis is negated for a specific strain of cannabis with a known cannabinoid profile.
[0021] 5. A topical composition prepared by the process of claim 1, whereby known specific cultivars of cannabis, with known cannabinoid profiles are extracted.
[0022] 6. A topical composition prepared by the process of claim 1, whereby the coconut oil was repeatedly heated (146-149 C) and congealed 5 times with a 50:50 mixture of cannabis Indica and Sativa as the extracting solvent, followed by filtration of the mixture and active THC concentration determined by HPLC.
[0023] 7. A topical composition prepared by the process of claim 6, whereby the coconut oil was repeatedly heated (146-149 C) and congealed 5 times with a 50:50 mixture of cannabis Indica and Sativa as the extracting solvent, followed by filtration of the mixture and active THC concentration determined by HPLC.
[0024] 8. A topical composition prepared by the process of claim 6, whereby the mixture of cannabis is negated for Indica only.
[0025] 9. A topical composition prepared by the process of claim 6, whereby the mixture of cannabis is negated for Sativa only.
A Cannabis Topical from Heat Treated Coconut Oil Inventors:
1. Erik William Mikkelsaar Industry I
ndustr PAI/J WMAD
Canada Canada 987 Balfour Street Fenwick, Ontario 2. Antony Paul Hornby, Ph.D.
P.O. Box 22008 Richmond, B.C.
Abstract [0001] A method is disclosed whereby by two subspecies of cannabis (Indica and Sativa) are mixed in equal weight portions, followed by repeated heating and congealing of the mixture in Virgin Coconut Oil to yield a topical lotion for use in the treatment of arthritic muscle and joint pain. Concentrations of the major cannabinoid actives in the lotion are determined using laboratory analysis by High Pressure Liquid Chromatography (HPLC).
Background to the Invention [0002] Patent No. W02004016277 teaches an extraction method using super critical fluid extraction of cannabinoids from plant material the method described here uses no fluid extraction procedure and does not substitute with synthetic analogues if extracted material is not available.
[0003] Patent No US2003191180 speaks to organic solvent extraction of cannabinoids from plant material plus the use of the invention of synthetic analogues.
The patent described here references only natural product material and coconut oil for extraction.
[0004] Patent No. W003063847 teaches anti-nausea formulation based on solvent extraction of THC-A. In the patent described here no extraction precedes activation of THC-A to THC.
[0005] Patent No. US2002086438 again teaches an organic solvent extraction of cannabinoids to be used in medicinal formulations plus a chelation step for ^-as a concentration enhancer. This patent describes the use of virgin coconut oil as the extraction solvent.
[0006] Patent No. US20120264818 Al speaks to an aprotic solvent (methyl sulfoxide) =for extraction of cannabinoids. This patent uses a heat processed, virgin coconut oil.
[0007] The efficacy of cannabis medicine has been known for many years across a broad range of ailments from addiction withdrawal to tremor. In addition, many thousands of years use with no evidence of fatal overdose lends great credence to its safety. However, as the result of roughly 100 years of prohibition in most of the western world its utilization as a medicine has yet to be realized.
[0008] Since the discovery of the receptor for ^9-tetrahydrocannabinol (T1-1C, cannabis' principle active) in the early 1990's, there's been an enormous resurgence in medical cannabis research, once again pointing the way to its efficacy and safety.
The former parameter, efficacy has problems in terms of the traditional means of administration (smoking) and oral dosing in that accurate dosing is not possible with unstandardized preparations and overdose (although not fatal, can be frightening) will occur.
[0009] Topical applications as a result of relatively slow uptake through the epidermis as a rule do not cause overdose and can be considered safer for this reason.
Topical administration is often advantageous for arthritic pain, since application can be made directly to the painful sight (hands, back, joints).
[0010] Cannabinoids are highly fat-soluble compounds and therefore readily dissolve in non-polar, hydrocarbon-like environments such as oils. Coconut oil contains an unusually high percentage of saturated fat (making it unsuitable for human oral consumption) and is therefore slow to oxidize and turn rancid. The virgin coconut oil also contains a relatively high content of medium chain triglycerides, plus lauric acid.
It is the unusual fat profile of coconut oil that elicits the unique heating and congealing properties of the oil, making it useful as an extracting solvent, plus penetrator.
[0011] Repeated heating (130-150T) and cooling of the oil greatly enhances the penetrating and delivery action, whereby viscosity, free fatty acid changes and oxidation lend to the desired preparation over a repeated heating and cooling cycle.
[0012] Addition of a 50:50 (by weight Indica ssp./Sativa ssp.) of the dried, ground, leaves and flowers of the cannabis plant (at approximately 5g cannabis raw material per 30 ml oil) to the mix, prior to heating is added to a slow cooker (Rival Crock Pot, model 3355, rated at 250 watts. 120 volts 50-60 cycle, CSA approved) and the temperature raised to between 146-149 C (295-300 F) for 5-7 hours, with occasional mixing.
[0013] The heat is then turned off and the mixture allowed to cool to the point of congealing (at roughly 23T), often taking overnight. This cycle is repeated 5 times.
[0014] The heat-treated coconut oil containing the extracted cannabinoids is then strained through a 220-mesh extractor bag, into a suitably sized glass collection vessel and allowed to congeal. A sample of the finished product is taken for HPLC
testing.
testing.
[00151 Determining the cannabinoid concentration of the finished product is essential knowledge of dosage and effect. This was done by measuring (by HPLC) the total decarboxy lated ^9-THC, plus the same for cannabidiol (CBD) and cannabinol (CBN).
also known is the amount of Cannabichromene (CBC) and Cannabigerol (CBG), present per milliliter of lotion.
[0016] Infusions such as those described [0011-0015] will provide concentrations of activated THC a 10mg/m1 or greater, depending on starting raw material.
Claims:
[0017] 1. A topical composition is disclosed whereby a 50:50 mixture of cannabis Indica and Sativa are extracted through coconut oil that has been heated (146-149 C) and cooled to congealing (28 C). The infusion is then, re-heated, filtered and tested for active THC concentration by HPLC.
[0018] 2. A topical composition prepared by the process of claim 1, whereby the mixture of cannabis is negated for Indica only.
[0019] 3. A topical composition prepared by the process of claim 1, whereby the mixture of cannabis is negated for Sativa only.
[0020] 4. A topical composition prepared by the process of claim 1, whereby the mixture of cannabis is negated for a specific strain of cannabis with a known cannabinoid profile.
[0021] 5. A topical composition prepared by the process of claim 1, whereby known specific cultivars of cannabis, with known cannabinoid profiles are extracted.
[0022] 6. A topical composition prepared by the process of claim 1, whereby the coconut oil was repeatedly heated (146-149 C) and congealed 5 times with a 50:50 mixture of cannabis Indica and Sativa as the extracting solvent, followed by filtration of the mixture and active THC concentration determined by HPLC.
[0023] 7. A topical composition prepared by the process of claim 6, whereby the coconut oil was repeatedly heated (146-149 C) and congealed 5 times with a 50:50 mixture of cannabis Indica and Sativa as the extracting solvent, followed by filtration of the mixture and active THC concentration determined by HPLC.
[0024] 8. A topical composition prepared by the process of claim 6, whereby the mixture of cannabis is negated for Indica only.
[0025] 9. A topical composition prepared by the process of claim 6, whereby the mixture of cannabis is negated for Sativa only.
A Cannabis Topical from Heat Treated Coconut Oil Inventors:
1. Erik William Mikkelsaar Industry I
ndustr PAI/J WMAD
Canada Canada 987 Balfour Street Fenwick, Ontario 2. Antony Paul Hornby, Ph.D.
P.O. Box 22008 Richmond, B.C.
Abstract [0001] A method is disclosed whereby by two subspecies of cannabis (Indica and Sativa) are mixed in equal weight portions, followed by repeated heating and congealing of the mixture in Virgin Coconut Oil to yield a topical lotion for use in the treatment of arthritic muscle and joint pain. Concentrations of the major cannabinoid actives in the lotion are determined using laboratory analysis by High Pressure Liquid Chromatography (HPLC).
Background to the Invention [0002] Patent No. W02004016277 teaches an extraction method using super critical fluid extraction of cannabinoids from plant material the method described here uses no fluid extraction procedure and does not substitute with synthetic analogues if extracted material is not available.
[0003] Patent No US2003191180 speaks to organic solvent extraction of cannabinoids from plant material plus the use of the invention of synthetic analogues.
The patent described here references only natural product material and coconut oil for extraction.
[0004] Patent No. W003063847 teaches anti-nausea formulation based on solvent extraction of THC-A. In the patent described here no extraction precedes activation of THC-A to THC.
[0005] Patent No. US2002086438 again teaches an organic solvent extraction of cannabinoids to be used in medicinal formulations plus a chelation step for ^-as a concentration enhancer. This patent describes the use of virgin coconut oil as the extraction solvent.
[0006] Patent No. US20120264818 Al speaks to an aprotic solvent (methyl sulfoxide) =for extraction of cannabinoids. This patent uses a heat processed, virgin coconut oil.
[0007] The efficacy of cannabis medicine has been known for many years across a broad range of ailments from addiction withdrawal to tremor. In addition, many thousands of years use with no evidence of fatal overdose lends great credence to its safety. However, as the result of roughly 100 years of prohibition in most of the western world its utilization as a medicine has yet to be realized.
[0008] Since the discovery of the receptor for ^9-tetrahydrocannabinol (T1-1C, cannabis' principle active) in the early 1990's, there's been an enormous resurgence in medical cannabis research, once again pointing the way to its efficacy and safety.
The former parameter, efficacy has problems in terms of the traditional means of administration (smoking) and oral dosing in that accurate dosing is not possible with unstandardized preparations and overdose (although not fatal, can be frightening) will occur.
[0009] Topical applications as a result of relatively slow uptake through the epidermis as a rule do not cause overdose and can be considered safer for this reason.
Topical administration is often advantageous for arthritic pain, since application can be made directly to the painful sight (hands, back, joints).
[0010] Cannabinoids are highly fat-soluble compounds and therefore readily dissolve in non-polar, hydrocarbon-like environments such as oils. Coconut oil contains an unusually high percentage of saturated fat (making it unsuitable for human oral consumption) and is therefore slow to oxidize and turn rancid. The virgin coconut oil also contains a relatively high content of medium chain triglycerides, plus lauric acid.
It is the unusual fat profile of coconut oil that elicits the unique heating and congealing properties of the oil, making it useful as an extracting solvent, plus penetrator.
[0011] Repeated heating (130-150T) and cooling of the oil greatly enhances the penetrating and delivery action, whereby viscosity, free fatty acid changes and oxidation lend to the desired preparation over a repeated heating and cooling cycle.
[0012] Addition of a 50:50 (by weight Indica ssp./Sativa ssp.) of the dried, ground, leaves and flowers of the cannabis plant (at approximately 5g cannabis raw material per 30 ml oil) to the mix, prior to heating is added to a slow cooker (Rival Crock Pot, model 3355, rated at 250 watts. 120 volts 50-60 cycle, CSA approved) and the temperature raised to between 146-149 C (295-300 F) for 5-7 hours, with occasional mixing.
[0013] The heat is then turned off and the mixture allowed to cool to the point of congealing (at roughly 23T), often taking overnight. This cycle is repeated 5 times.
[0014] The heat-treated coconut oil containing the extracted cannabinoids is then strained through a 220-mesh extractor bag, into a suitably sized glass collection vessel and allowed to congeal. A sample of the finished product is taken for HPLC
testing.
[0015] Determining the cannabinoid concentration of the finished product is essential knowledge of dosage and effect. This was done by measuring (by HPLC) the total decarboxylated "9-T11c, plus the same for cannabidiol (CBD) and cannabinol (CBN), also known is the amount of Cannabichromene (CBC) and Cannabigerol (CBG), present per milliliter of lotion.
[0016] Infusions such as those described [0011-0015] will provide concentrations of activated THC a 10mg/m1 or greater, depending on starting raw material.
Claims:
Claims:
[0017] 1. A topical composition is disclosed whereby a 50:50 mixture of cannabis Indica and Sativa are extracted through coconut oil that has been heated (146-149 'C) and cooled to congealing (28 'V). The infusion is then, re-heated, filtered and tested for active THC concentration by HPLC.
[0018] 2. A topical composition prepared by the process of claim 1, whereby the mixture of cannabis is negated for Indica only.
[0019] 3. A topical composition prepared by the process of claim 1, whereby the mixture of cannabis is negated for Sativa only.
[0020] 4. A topical composition prepared by the process of claim 1, whereby the mixture of cannabis is negated for a specific strain of cannabis with a known cannabinoid profile.
[0021] 5. A topical composition prepared by the process of claim 1, whereby known specific cultivars of cannabis, with known cannabinoid profiles are extracted.
[0022] 6. A topical composition prepared by the process of claim 1, whereby the coconut oil was repeatedly heated (146-149 C) and congealed 5 times with a 50:50 mixture of cannabis Indica and Sativa as the extracting solvent, followed by filtration of the mixture and active TI-IC concentration determined by HPLC.
[0023] 7. A topical composition prepared by the process of claim 6, whereby the coconut oil was repeatedly heated (146-149 C) and congealed 5 times with a 50:50 mixture of cannabis Indica and Saliva as the extracting solvent, followed by filtration of the mixture and active THC concentration determined by HPLC.
[0024] 8. A topical composition prepared by the process of claim 6, whereby the mixture of cannabis is negated for Indica only.
[0025] 9. A topical composition prepared by the process of claim 6, whereby the mixture of cannabis is negated for Sativa only.
Claims (3)
10016] Infusions such as those described [0011-0015] will provide concentrations of activated THC a 10mg/m1 or greater, depending on starting raw material.
Claims:
[0017] 1. A topical composition is disclosed whereby a 50:50 mixture of cannabis Indica and Sativa are extracted through coconut oil that has been heated (146-149 °C) and cooled to congealing (28°C). The infusion is then, re-heated, filtered and tested for active THC concentration by HPLC.
[0018] 2. A topical composition prepared by the process of claim 1, whereby the mixture of cannabis is negated for Indica only.
[0019] 3. A topical composition prepared by the process of claim 1, whereby the mixture of cannabis is negated for Sativa only.
[0020] 4. A topical composition prepared by the process of claim 1, whereby the mixture of cannabis is negated for a specific strain of cannabis with a known cannabinoid profile.
[0021] 5. A topical composition prepared by the process of claim 1, whereby known specific cultivars of cannabis, with known cannabinoid profiles are extracted.
[0022] 6. A topical composition prepared by the process of claim 1, whereby the coconut oil was repeatedly heated (146-149 °C) and congealed 5 times with a 50:50 mixture of cannabis Indica and Sativa as the extracting solvent, followed by filtration of the mixture and active THC concentration determined by HPLC.
[0023] 7. A topical composition prepared by the process of claim 6, whereby the coconut oil was repeatedly heated (146-149 °C) and congealed 5 times with a 50:50 mixture of cannabis indica and Sativa as the extracting solvent, followed by filtration of the mixture and active TFIC concentration determined by HPLC.
[0024] 8. A topical composition prepared by the process of claim 6, whereby the mixture of cannabis is negated for Indica only.
[0025] 9. A topical composition prepared by the process of claim 6, whereby the mixture of cannabis is negated for Sativa only.
[0026] 10. A topical composition prepared by the process of claim 6, whereby the mixture of cannabis is negated for a specific cultivar of cannabis with known cannabinoid profile only.
[0027] Preferably, the topical composition, as described herein, is a liquid that can be easily applied to the area of pain.
[0028] The topical compositions, as described herein, can be applied to any bodily region needing treatment including skin, ears, arms, hands, feet, legs, bac.k, head, anus, oral cavity, areas around eyes, lips, neck, but should not be taken orally.
[0029] The topical compositions, as described herein, can be applied to a patch for skin application.
[0030] The invention can now be illustrated by a number of examples, but not limited to these examples. All descriptions of times, temperatures, devices, and other parts of the disclosure are as described in example 1 and yield a topical composition that is liquid and can be applied for other uses.
Examples [0031] Preparation of a Topical Liquid 200 grams of dried, ground, cannabis leaves and flowers were placed in a cooking vessel and covered with 1 litre of virgin coconut oil. The mixture was heated from 5-7 hours at between 146 and 149 degrees Celsius, then allowed to cool for 10 hours to roughly 23 degrees Celsius when it congeals. The mixture was then re-heated to the same preceding temperatures (146-149 °C) for another 7 hours and the mixture poured through a 220 mesh (sieving) extractor bag into a collection vessel.
The topical liquid was re-congealed as the finished product, that can now be re-heated and find a number of uses.
Example I Preparation of a Topical Patch [0032] By applying an ml dose amount to a blank topical patch and attaching to areas of body pain will bring relief within 90 minutes.
Example 2 Preparation of a topical bandage [0033] By applying an ml dose amount to a blank bandage and attaching to areas of body pain and abrasion will bring about pain relief within 90 minutes and speed healing.
Example 3 Preparation of a topical composition 1) [0034] A fifty-eight year old male with a previous femur fracture, shortening of the bone occurred that left the muscles prone to spasm. By rubbing the coconut oil/cannabis mixture all over the thigh, the spasms immediately stopped, and stayed away for 1-3 days. D.C.
2.) [0035] A sixty year old male with eczema applied roughly 10 ml to the affected area and found pain and itching significantly reduced in 30 minutes, plus his skin condition improved greatly after receiving the topical preparation. E.B.
3.) [0036] A forty-two year old female with migraines applied a small amount to her temples, face and neck and found migraine pain significantly reduced within 30 minutes, continued use prevented migraine onset and severity.
[0015] Determining the cannabinoid concentration of the finished product is essential knowledge of dosage and effect. This was done by measuring (by HPLC) the total decarboxylated ^9-THC, plus the same for cannabidiol (CBD) and cannabinol (CBN), also known is the amount of Cannabichromene (CBC) and Cannabigerol (CBG), present per milliliter of lotion.
[0016] Infusions such as those described [0011-0015] will provide concentrations of activated THC a 10mg/ml or greater, depending on starting raw material.
Claims:
[0017] 1. A topical composition is disclosed whereby a 50:50 mixture of cannabis Indica and Sativa are extracted through coconut oil that has been heated (146-149 °C) and cooled to congealing (28 °C). The infusion is then. re-heated, filtered and tested for active THC concentration by HPLC.
[0018] 2. A topical composition prepared by the process of claim 1, whereby the mixture of cannabis is negated for Indica only.
[0019] 3. A topical composition prepared by the process of claim 1, whereby the mixture of cannabis is negated for Sativa only.
[0020] 4. A topical composition prepared by the process of claim 1, whereby the mixture of cannabis is negated for a specific strain of cannabis with a known cannabinoid profile.
[0021] 5. A topical composition prepared by the process of claim 1, whereby known specific cultivars of cannabis, with known cannabinoid profiles are extracted.
[0022] 6. A topical composition prepared by the process of claim 1. whereby the coconut oil was repeatedly heated (146-149 °C) and congealed 5 times with a 50:50 mixture of cannabis Indica and Saliva as the extracting solvent, followed by filtration of the mixture and active THC concentration determined by HPLC.
[0023] 7. A topical composition prepared by the process of claim 6, whereby the coconut oil was repeatedly heated (146-149 ° C) and congealed 5 times with a 50:50 mixture of cannabis Indica and Sativa as the extracting solvent, followed by filtration of the mixture and active THC concentration determined by HPLC.
[0024] 8. A topical composition prepared by the process of claim 6, whereby the mixture of cannabis is negated for Indica only.
[0025] 9. A topical composition prepared by the process of claim 6, whereby the mixture of cannabis is negated for Sativa only.
[0026] 10. A topical composition prepared by the process of claim 6, whereby the mixture of cannabis is negated for a specific cultivar of cannabis with known cannabinoid profile only.
[0027] Preferably, the topical composition. as described herein, is a liquid that can be easily applied to the area of pain.
[0028] The topical compositions, as described herein, can be applied to any bodily region needing treatment including skin, ears, arms, hands, feet, legs, back, head, anus, oral cavity, areas around eyes, lips, neck, but should not be taken orally.
[0029] The topical compositions, as described herein, can be applied to a patch for skin application.
[0030] The invention can now be illustrated by a number of examples, but not limited to these examples. All descriptions of times, temperatures, devices, and other parts of the disclosure are as described in example 1 and yield a topical composition that is liquid and can be applied for other uses.
Examples [0031] Preparation of a Topical Liquid 200 grams of dried, ground, cannabis leaves and flowers were placed in a cooking vessel and covered with 1 litre of virgin coconut oil. The mixture was heated from 5-7 hours at between 146 and 149 degrees Celsius, then allowed to cool for 10 hours to roughly 23 degrees Celsius when it congeals. The mixture was then re-heated to the same preceding temperatures (146-149 °C) for another 7 hours and the mixture poured through a 220 mesh (sieving) extractor bag into a collection vessel.
The topical liquid was re-congealed as the finished product, that can now be re-heated and find a number of uses.
Example I Preparation of a Topical Patch [0032] By applying an ml dose amount to a blank topical patch and attaching to areas of body pain will bring relief within 90 minutes.
Example 2 Preparation of a topical bandage [0033] By applying an ml dose amount to a blank bandage and attaching to areas of body pain and abrasion will bring about pain relief within 90 minutes and speed healing.
Example 3 Preparation of a topical composition
1) [0034] A fifty-eight year old male with a previous femur fracture, shortening of the bone occurred that left the muscles prone to spasm. By rubbing the coconut oil/cannabis mixture all over the thigh, the spasms immediately stopped, and stayed away for 1-3 days. D.C.
2.) [0035] A sixty year old male with eczema applied roughly 10 ml to the affected area and found pain and itching significantly reduced in 30 minutes, plus his skin condition improved greatly after receiving the topical preparation. E.B.
3.) [0036] A forty-two year old female with migraines applied a small amount to her temples, face and neck and found migraine pain significantly reduced within 30 minutes, continued use prevented migraine onset and severity.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2859930A CA2859930A1 (en) | 2014-09-22 | 2014-09-22 | A cannabis topical from heat treated cocount oil |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2859930A CA2859930A1 (en) | 2014-09-22 | 2014-09-22 | A cannabis topical from heat treated cocount oil |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2859930A1 true CA2859930A1 (en) | 2016-03-22 |
Family
ID=55539872
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2859930A Pending CA2859930A1 (en) | 2014-09-22 | 2014-09-22 | A cannabis topical from heat treated cocount oil |
Country Status (1)
| Country | Link |
|---|---|
| CA (1) | CA2859930A1 (en) |
Cited By (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019030762A2 (en) | 2017-08-09 | 2019-02-14 | Stahl Veronica | Cannabis and derivatives thereof for the treatment of pain and inflammation related with dental pulp and bone regeneration related to dental jaw bone defects |
| US20190307719A1 (en) * | 2016-08-03 | 2019-10-10 | Zelda Therapeutics Operations Pty Ltd | Cannabis composition |
| US10512856B1 (en) | 2019-01-11 | 2019-12-24 | Gildrien Farm, LLC | Method of extracting one or more chemical extracts from a plant product |
| US10617636B2 (en) | 2016-04-15 | 2020-04-14 | Sre Wellness, Inc. | Cannabis infused sweeteners and elixirs |
| US10624844B2 (en) | 2016-04-15 | 2020-04-21 | Sre Wellness, Inc. | Cannabinoid compositions comprising cannabis oil and methods of making thereof |
| US11141680B2 (en) | 2019-01-11 | 2021-10-12 | Gildrien Farm, LLC | Method of extracting one or more chemical extracts from a plant product |
| US11266159B2 (en) | 2019-10-01 | 2022-03-08 | Michael William Randel | Method for making cannabinoids infused consumables |
| US11311589B2 (en) | 2020-09-30 | 2022-04-26 | Michael William Randel | Cannabinoids infused coffee beans and raw nuts |
| US11464819B2 (en) | 2020-09-30 | 2022-10-11 | Michael William Randel | Cannabinoids infused consumables and non-consumables |
| US11464818B2 (en) | 2020-09-30 | 2022-10-11 | Michael William Randel | Cannabinoids infused consumables |
| US11816133B2 (en) | 2022-03-30 | 2023-11-14 | Oliver Siegel | Crowdsourced problem-solution directory |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| US12097293B2 (en) | 2019-10-14 | 2024-09-24 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| US12121617B2 (en) | 2019-10-14 | 2024-10-22 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
-
2014
- 2014-09-22 CA CA2859930A patent/CA2859930A1/en active Pending
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10617636B2 (en) | 2016-04-15 | 2020-04-14 | Sre Wellness, Inc. | Cannabis infused sweeteners and elixirs |
| US10624844B2 (en) | 2016-04-15 | 2020-04-21 | Sre Wellness, Inc. | Cannabinoid compositions comprising cannabis oil and methods of making thereof |
| US20190307719A1 (en) * | 2016-08-03 | 2019-10-10 | Zelda Therapeutics Operations Pty Ltd | Cannabis composition |
| US20220362208A1 (en) * | 2016-08-03 | 2022-11-17 | Zelda Therapeutics Operations Pty Ltd | Cannabis composition |
| WO2019030762A2 (en) | 2017-08-09 | 2019-02-14 | Stahl Veronica | Cannabis and derivatives thereof for the treatment of pain and inflammation related with dental pulp and bone regeneration related to dental jaw bone defects |
| US11612581B2 (en) | 2017-08-09 | 2023-03-28 | Cannibite Bvba | Cannabis and derivatives thereof for the treatment of pain and inflammation related with dental pulp and bone regeneration related to dental jaw bone defects |
| US10512856B1 (en) | 2019-01-11 | 2019-12-24 | Gildrien Farm, LLC | Method of extracting one or more chemical extracts from a plant product |
| US11141680B2 (en) | 2019-01-11 | 2021-10-12 | Gildrien Farm, LLC | Method of extracting one or more chemical extracts from a plant product |
| US11266159B2 (en) | 2019-10-01 | 2022-03-08 | Michael William Randel | Method for making cannabinoids infused consumables |
| US12016829B2 (en) | 2019-10-11 | 2024-06-25 | Pike Therapeutics Inc. | Pharmaceutical composition and method for treating seizure disorders |
| US12121617B2 (en) | 2019-10-14 | 2024-10-22 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| US12097293B2 (en) | 2019-10-14 | 2024-09-24 | Pike Therapeutics Inc. | Transdermal delivery of cannabidiol |
| US11464819B2 (en) | 2020-09-30 | 2022-10-11 | Michael William Randel | Cannabinoids infused consumables and non-consumables |
| US11464818B2 (en) | 2020-09-30 | 2022-10-11 | Michael William Randel | Cannabinoids infused consumables |
| US11311589B2 (en) | 2020-09-30 | 2022-04-26 | Michael William Randel | Cannabinoids infused coffee beans and raw nuts |
| US11816133B2 (en) | 2022-03-30 | 2023-11-14 | Oliver Siegel | Crowdsourced problem-solution directory |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA2859930A1 (en) | A cannabis topical from heat treated cocount oil | |
| CN107998020B (en) | Skin cream with anti-allergic effect | |
| CN104147533B (en) | A kind of promoting blood circulation, removing blood stasis and relieving pain emulsifiable paste and preparation method thereof | |
| CN102228566B (en) | Drug powder for treating burn or scald | |
| CN105663385B (en) | A kind of anaesthetic analgesia ointment and preparation method thereof | |
| Sonalkar et al. | Formulation and evaluation of polyherbal cosmetic cream | |
| CN107184483A (en) | High penetration camellia massage essential oil promoting blood circulation and removing obstruction in channels and preparation method thereof | |
| KR20020025196A (en) | Oil from momordica charantia l., its method of preparation and uses | |
| CN106389582A (en) | Universal ointment for babies and preparation method of universal ointment | |
| CA2829792C (en) | Treatment of vaginal atrophy as novel indication for myrrh | |
| CN105126037B (en) | A kind of ointment for treating bone fracture and injury of the extract containing natural component and preparation method thereof | |
| CN104027439B (en) | Compositions and preparation method thereof | |
| CN104383286A (en) | Paste for treating burns and scalds and preparation method of paste | |
| CN1162454A (en) | Green bamboo liquid for fumigation of eyes and preparation thereof | |
| CN108703899B (en) | Skin-care massage essential oil | |
| CA2620242A1 (en) | Topical soothing bruise healing preparation | |
| Kardono et al. | Development of papaya latex, papaya extract (Carica papaya L.) and yam bean tuber extract (Pachyrrhizus erosus (L.) Urb.) for skin lightening lotion based on tyrosinase inhibition and antioxidant activities | |
| WO2006002443A1 (en) | Pharmaceutical or cosmetic preparation based on kigelia africana | |
| US11395813B1 (en) | Cannabinoids based pharmaceutical composition | |
| Zohreh et al. | Medicinal herbs effective on the skin | |
| US20230255899A1 (en) | Cannabinoid Monoterpene Based Pharmaceutical Topical Composition For MusculoSkeletal Pain | |
| Menezes et al. | Evaluation of anti-inflammatory and antinociceptive activities of the Austroplenckia populnea extract in topical formulations | |
| RU2575583C1 (en) | Biologically active liniment | |
| JP6775314B2 (en) | Residual chlorine scavenger, residual chlorine scavenging bath composition, and residual chlorine scavenging skin cosmetics | |
| CN106074867A (en) | A kind of oil tea oil ointment machin its preparation method |